国家药监局等三部门发文 奖励药品器械质量问题“吹哨人”

Group 1 - The core viewpoint of the announcement is to encourage internal whistleblowers to report major violations related to the quality and safety of drugs and medical devices, thereby enhancing regulatory oversight and public trust in these products [1][2] - The announcement specifies that internal whistleblowers must provide clear evidence of violations that have not been previously known to regulatory authorities, and that these reports must lead to administrative penalties or criminal prosecutions [1][2] - The policy aims to leverage the detailed and credible information that internal whistleblowers can provide, which is expected to increase the likelihood of identifying significant risks and violations in the pharmaceutical and medical device sectors [1][2] Group 2 - The reward system for whistleblowers includes a maximum reward of 1 million yuan per case, with the specific amount determined by discussions between the drug supervision department and local government finance departments [3] - The implementation of this policy is part of a broader initiative to promote social governance in drug and medical device quality safety, with the aim of preventing and curbing major illegal activities in the sector [2][3] - Following the announcement, some provincial drug supervision departments have begun to adopt similar policies to encourage internal reporting of violations, indicating a trend towards more robust regulatory frameworks in the industry [3]